Under construction – not a live service
Sign in
Not yet taking people in United StatesNo phase

Measures insulin sensitivity with an automated glucose clamp in adults

Tests an automated glucose clamp in adults with obesity or type 2 diabetes.

Key facts

Who runs it
Profil Institut für Stoffwechselforschung GmbH
Where
Webster, United StatesSee the site
Trial code
Registry title
Clinical Research Trial to Study Insulin Sensitivity Using Automated Glucose Clamp Technology
Status
Not yet recruiting
People taking part
50 people, planned
Starts
1 Feb 2027
Expected to end
1 Feb 2028
Type of study
Observational
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are obese or who have type 2 diabetes, to study insulin sensitivity with an automated glucose clamp.

Age
18 to 65 years
Sex
Men and women can join.
Disease stage
Obese people, or people with type 2 diabetes. BMI above 30 kg/m2.
Earlier treatment
No medicinal product in clinical development within 30 days or at least 5 half-lives before randomisation.

Main reasons for not taking part

  • Pregnant or breast-feeding women
  • Daily smoker or using nicotine substitute products
  • Positive test for hepatitis B antigen or HIV-1/2
  • Serious infection in the last four weeks or signs of acute illness
  • Previous participation in this trial

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Signed and dated informed consent has been obtained
  • Participant is male or female
  • Age between 18 and 65 years, both inclusive
  • Obese people or people diagnosed with type 2 diabetes
  • BMI, > 30 kg/m2, for obese participants and people with type 2 diabetes
  • Has venous access sufficient to allow cannulation for blood sampling as required by the protocol

Who cannot take part

  • Previous participation in this trial. Participation is defined as having completed at least one clamp
  • A positive result in the alcohol and/or urine drug screen at the screening visit
  • Current use of systemic medication that could interfere with the interpretation of the trial endpoints (insulin sensitivity assessment), as judged by the Investigator
  • History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
  • Any serious systemic infectious disease within the last four weeks, as judged by the investigator
  • Signs of acute illness as judged by the investigator
  • Significant history of alcoholism as judged by the investigator or consuming more than 24.0 grams alcohol/day (for males), 12.0 grams alcohol/day (for females) on average
  • Tested positive for hepatitis Bs antigen
  • Tested positive for hepatitis C antibodies. (Presence of hepatitis C antibodies will not lead to exclusion if liver function tests are normal and a hepatitis C polymerase chain reaction is negative)
  • Positive result to the test for HIV-1/2 antibodies or HIV-1 antigen
  • Clinically significant abnormal screening laboratory tests, as judged by the investigator
  • Receipt of any medicinal product in clinical development within 30 days or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomisation in this trial
  • Clinically relevant comorbidity, capable of constituting a risk for the participant when participating in the trial or of interfering with the interpretation of data
  • Clinically significant abnormal findings for vital signs and ECG recordings, as judged by the investigator
  • Daily smoker or using nicotine substitute products
  • Blood donation or blood loss of more than 500 mL within the last 3 months
  • If female, pregnancy or breast-feeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Profil USWebster, United StatesContact: Karim MohammedNo longer taking part

About the trial

What the trial wants to find out

This trial will establish fully-automated glucose clamping using state-of-the-art technology (ClampArt®) at a US based clinical research center

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Clinical Research Trial to Study Insulin Sensitivity Using Automated Glucose Clamp Technology
Plain-language title
Measures insulin sensitivity with an automated glucose clamp in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07913698, who can take part
Record updated
3 November 2026